Cryopreserved Hair Follicles for Disease and Cell Replacement
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorAcorn Biolabs Inc.
About this trial
To explore the application of cells expanded from plucked hair follicles after collection, transport, and cryopreservation, in disease modeling and cell-based therapies.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Gender: Male or Female.
Age: ≥18 and ≤80 years.
Language proficiency: Able to read and understand English.
Informed consent: Willing to provide written, informed consent to participate in all study activities.
Disqualifiers
Scalp/Hair Disorders: Subjects diagnosed with active scalp infections or inflammatory skin conditions.
Systemic Conditions: Subjects with chronic illnesses, such as autoimmune diseases or diabetes, that may impact scalp health or wound healing.
Medications: Subjects on immunosuppressants, steroids, or other medications associated with hair loss.
Trial population
Healthy population, aged 18-80, without scalp or hair disorders, chronic illnesses that may impact scalp health or wound healing, and not on immunosuppressants, steroids, or medications that cause hair loss.
Trial design
Design model
Cohort
Time perspective
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
100 Participants
are grouped into 1 trial groupGroup A: Hair Follicle Donors
Trial outcomes
Primary outcomes
1
Characterize primary cellular outgrowth(s)
10 hair follicles will be placed in a tissue culture plate per participants. Over the course of 30 days, the outgrowth percentage (the number of outgrowths present out of 10 will be monitored and the confluency (percent of cells present in relation to surface area) will be noted for each participant.
Time frame
30 days2
Evaluate functional stem cell generation and induced pluripotent stem cell line(s) from primary outgrowth(s)
1 million keratinocytes will be taken for reprogramming for each participant. The number of iPS colonies observed on day 21 will be noted, resulting in a reprogramming efficiency score.
Time frame
21 days3
Evaluate and characterize differentiation of stem cell lines into functional cell types required for various disease states and cell-based application(s)
iPS cell lines which have been confirmed to be pluripotent will be differentiated into pancreatic progenitor cells and hematopoietic stem cells. The cells will be analyzed using FLOW cytometry and the percentage of double positive cells will be noted for each participant. This will be repeated for multiple pathways such as the hematopoietic and endothelial lineage(s).
Time frame
30 daysLocations
1Map coordinates are unavailable for these locations. Locations are shown below instead.
Acorn BiolabsRecruitingM5R 0C7, Toronto, Quebec
Canada
CanadaSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov